High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE -/- mice

BMC Microbiol. 2016 Nov 8;16(1):264. doi: 10.1186/s12866-016-0883-4.

Abstract

Background: Atherosclerosis appears to have multifactorial causes - microbial component like lipopolysaccharides (LPS) and other pathogen associated molecular patterns may be plausible factors. The gut microbiota is an ample source of such stimulants, and its dependent metabolites and altered gut metagenome has been an established link to atherosclerosis. In this exploratory pilot study, we aimed to elucidate whether microbial intervention with probiotics L. rhamnosus GG (LGG) or pharmaceuticals telmisartan (TLM) could improve atherosclerosis in a gut microbiota associated manner.

Methods: Atherosclerotic phenotype was established by 12 weeks feeding of high fat (HF) diet as opposed to normal chow diet (ND) in apolipoprotein E knockout (ApoE-/-) mice. LGG or TLM supplementation to HF diet was studied.

Results: Both LGG and TLM significantly reduced atherosclerotic plaque size and improved various biomarkers including endotoxin to different extents. Colonial microbiota analysis revealed that TLM restored HF diet induced increase in Firmicutes/Bacteroidetes ratio and decrease in alpha diversity; and led to a more distinct microbial clustering closer to ND in PCoA plot. Eubacteria, Anaeroplasma, Roseburia, Oscillospira and Dehalobacteria appeared to be protective against atherosclerosis and showed significant negative correlation with atherosclerotic plaque size and plasma adipocyte - fatty acid binding protein (A-FABP) and cholesterol.

Conclusion: LGG and TLM improved atherosclerosis with TLM having a more distinct alteration in the colonic gut microbiota. Altered bacteria genera and reduced alpha diversity had significant correlations to atherosclerotic plaque size, plasma A-FABP and cholesterol. Future studies on such bacterial functional influence in lipid metabolism will be warranted.

Keywords: Atherosclerosis; Gut microbitoa; LGG; Probiotics; Telmisartan.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Apolipoproteins E / deficiency
  • Apolipoproteins E / genetics
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Atherosclerosis / microbiology
  • Atherosclerosis / pathology
  • Benzimidazoles / administration & dosage*
  • Benzoates / administration & dosage*
  • Cholesterol / blood*
  • Colon / microbiology*
  • Diet, High-Fat / adverse effects
  • Fatty Acid-Binding Proteins / blood*
  • Female
  • Gastrointestinal Microbiome*
  • Humans
  • Lactobacillus rhamnosus / physiology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Pilot Projects
  • Probiotics / administration & dosage*
  • Telmisartan

Substances

  • Apolipoproteins E
  • Benzimidazoles
  • Benzoates
  • Fabp4 protein, mouse
  • Fatty Acid-Binding Proteins
  • Cholesterol
  • Telmisartan